FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1489652607> ?p ?o ?g. }

• W1489652607 abstract "OBJECTIVE: To characterize MRI-EDSS associations in a subset of subjects treated for up to 20 years in the US Glatiramer Acetate open-label (OL) extension trial.BACKGROUND: Identifying MRI outcomes that correlate with disability remains an MS research priority.DESIGN/METHODS: Following the placebo-controlled phase of the US Glatiramer Acetate pivotal trial, subjects entered the GA 20mg daily open-label extension in 1994. MRI scans were obtained in a subset of these patients in 2012. EDSS closest to the MRI scan was used for cross-sectional Spearman rank-correlation coefficient analyses.RESULTS: Sixty-four of 74 subjects (86%) participated in this MRI substudy. EDSS scores (mean 3.42; 0-8) were correlated with whole brain (WB) volume (r=-0.42, P=.001), gray matter (GM) volume (r=-0.35, P=.005), MRS N-acetylaspartate/N-acetylaspartylglutamate (NAA/NAAG) levels (r=-0.54, P<.001), cingulate cortical thickness (r=-0.31, P=.014), T1 lesion volume (r=0.41, P=.001), and T2 lesion volume (r=0.35, P=.005). There was no significant correlation with white matter volume, WB MTR, WB DTI metrics including FA and MD, or global cortical thickness. Subjects stratified by quartiles according to the MRI correlates of disability demonstrate EDSS differences at the quartile-level up to 15 years prior to the scan. Statistical models describing the relationship of conventional and non-conventional MRI measures to the longitudinal course of disability accumulation in this unique subject cohort, which includes over two decades of continuous treatment and follow-up, will be presented.CONCLUSIONS: The strongest cross-sectional MRI correlate of MS-related disability in this cohort was MRS NAA/NAAG, followed by WB volume, T1 lesion volume, GM volume, T2 lesion volume, and cingulate cortical thickness.Study Supported by: Teva Pharmaceutical Industries, Petach Tiqva, Israel. Disclosure: Dr. Khan has received personal compensation for activities with Biogen Idec, Genzyme Corporation, Novartis, and Teva Neuroscience. Dr. Khan has received research funding from NIH, NINDS, National Multiple Sclerosis Society, Teva Neuroscience, Biogen Idec, Genzyme Corporation, Roche, and Novartis. Dr. Bao has nothing to disclose. Dr. Shah has nothing to disclose. Dr. Ramesh has nothing to disclose. Dr. Caon has received personal compensation for activities with Teva Neuroscience, Novartis, Genzyme Inc., and Biogen Idec. Dr. Santiago Martinez has nothing to disclose. Dr. Latif has nothing to disclose. Dr. Aronov has nothing to disclose. Dr. Zak has nothing to disclose. Dr. Sidi has received personal compensation for activities with Teva Neuroscience. Dr. Kolodny has received personal compensation for activities with Teva Neuroscience as an employee. Dr. Kolodny holds stock and/or stock options in Teva Neuroscience which sponsored research in which Dr. Kolodny was involved as an investigator." @default.
• W1489652607 created "2016-06-24" @default.
• W1489652607 creator A5000584276 @default.
• W1489652607 creator A5014213879 @default.
• W1489652607 creator A5015410912 @default.
• W1489652607 creator A5015964287 @default.
• W1489652607 creator A5039473753 @default.
• W1489652607 creator A5043505835 @default.
• W1489652607 creator A5047666237 @default.
• W1489652607 creator A5048836412 @default.
• W1489652607 creator A5051172260 @default.
• W1489652607 creator A5056450316 @default.
• W1489652607 creator A5081342306 @default.
• W1489652607 date "2014-04-08" @default.
• W1489652607 modified "2023-09-26" @default.
• W1489652607 title "MRI Correlates Of Disability: Neuroimaging Substudy At 20 Years In The Ongoing US Glatiramer Acetate Open-Label Extension Study (P3.196)" @default.
• W1489652607 hasPublicationYear "2014" @default.
• W1489652607 type Work @default.
• W1489652607 sameAs 1489652607 @default.
• W1489652607 citedByCount "0" @default.
• W1489652607 crossrefType "journal-article" @default.
• W1489652607 hasAuthorship W1489652607A5000584276 @default.
• W1489652607 hasAuthorship W1489652607A5014213879 @default.
• W1489652607 hasAuthorship W1489652607A5015410912 @default.
• W1489652607 hasAuthorship W1489652607A5015964287 @default.
• W1489652607 hasAuthorship W1489652607A5039473753 @default.
• W1489652607 hasAuthorship W1489652607A5043505835 @default.
• W1489652607 hasAuthorship W1489652607A5047666237 @default.
• W1489652607 hasAuthorship W1489652607A5048836412 @default.
• W1489652607 hasAuthorship W1489652607A5051172260 @default.
• W1489652607 hasAuthorship W1489652607A5056450316 @default.
• W1489652607 hasAuthorship W1489652607A5081342306 @default.
• W1489652607 hasConcept C105795698 @default.
• W1489652607 hasConcept C118552586 @default.
• W1489652607 hasConcept C126322002 @default.
• W1489652607 hasConcept C126838900 @default.
• W1489652607 hasConcept C143409427 @default.
• W1489652607 hasConcept C146638467 @default.
• W1489652607 hasConcept C159744936 @default.
• W1489652607 hasConcept C2778577042 @default.
• W1489652607 hasConcept C2780640218 @default.
• W1489652607 hasConcept C2780892749 @default.
• W1489652607 hasConcept C2781192897 @default.
• W1489652607 hasConcept C2989005 @default.
• W1489652607 hasConcept C33923547 @default.
• W1489652607 hasConcept C44249647 @default.
• W1489652607 hasConcept C58693492 @default.
• W1489652607 hasConcept C68443243 @default.
• W1489652607 hasConcept C71924100 @default.
• W1489652607 hasConcept C72563966 @default.
• W1489652607 hasConceptScore W1489652607C105795698 @default.
• W1489652607 hasConceptScore W1489652607C118552586 @default.
• W1489652607 hasConceptScore W1489652607C126322002 @default.
• W1489652607 hasConceptScore W1489652607C126838900 @default.
• W1489652607 hasConceptScore W1489652607C143409427 @default.
• W1489652607 hasConceptScore W1489652607C146638467 @default.
• W1489652607 hasConceptScore W1489652607C159744936 @default.
• W1489652607 hasConceptScore W1489652607C2778577042 @default.
• W1489652607 hasConceptScore W1489652607C2780640218 @default.
• W1489652607 hasConceptScore W1489652607C2780892749 @default.
• W1489652607 hasConceptScore W1489652607C2781192897 @default.
• W1489652607 hasConceptScore W1489652607C2989005 @default.
• W1489652607 hasConceptScore W1489652607C33923547 @default.
• W1489652607 hasConceptScore W1489652607C44249647 @default.
• W1489652607 hasConceptScore W1489652607C58693492 @default.
• W1489652607 hasConceptScore W1489652607C68443243 @default.
• W1489652607 hasConceptScore W1489652607C71924100 @default.
• W1489652607 hasConceptScore W1489652607C72563966 @default.
• W1489652607 hasOpenAccess W1489652607 @default.
• W1489652607 hasRelatedWork W1120863371 @default.
• W1489652607 hasRelatedWork W1512710245 @default.
• W1489652607 hasRelatedWork W1602946123 @default.
• W1489652607 hasRelatedWork W1914720554 @default.
• W1489652607 hasRelatedWork W2167657465 @default.
• W1489652607 hasRelatedWork W2210506145 @default.
• W1489652607 hasRelatedWork W2259240662 @default.
• W1489652607 hasRelatedWork W2320230590 @default.
• W1489652607 hasRelatedWork W2327497376 @default.
• W1489652607 hasRelatedWork W2561205926 @default.
• W1489652607 hasRelatedWork W2582486407 @default.
• W1489652607 hasRelatedWork W2596114573 @default.
• W1489652607 hasRelatedWork W2746854006 @default.
• W1489652607 hasRelatedWork W2885106432 @default.
• W1489652607 hasRelatedWork W2906693279 @default.
• W1489652607 hasRelatedWork W2909569477 @default.
• W1489652607 hasRelatedWork W890671167 @default.
• W1489652607 hasRelatedWork W1886148765 @default.
• W1489652607 hasRelatedWork W2587810310 @default.
• W1489652607 hasRelatedWork W3088842024 @default.
• W1489652607 hasVolume "82" @default.
• W1489652607 isParatext "false" @default.
• W1489652607 isRetracted "false" @default.
• W1489652607 magId "1489652607" @default.
• W1489652607 workType "article" @default.